News

Discover how Hempmon Shares celebrated the 116th International Women’s Day in Yunnan. From heartfelt leadership speeches to festive surprises, see how we honor the "Radiant Brilliance" and vital contributions of our female workforce to the success of Hempmon Pharmaceutical.

CBG and CBGA are poised to become vital additions to the family of therapeutic cannabinoids, offering unique benefits without the psychoactive side effects associated with THC.

According to local reports from San Jose Ahora, "With the introduction of the new pricing, the price for the Alpha variety has risen from $480 to $485; the Beta variety from $500 to $505; the Gamma variety from $560 to $565; and the Epsilon variety from $610 to $615."

A recent long-term study published in Israel indicates that medical cannabis can significantly alleviate pain and provide neuroprotection by acting through the endocannabinoid system with minimal side effects. Adding medical cannabis to standard therapies reduces pain and improves blood sugar levels.

Cannabidiol (CBD) is being incorporated into a growing array of products, ranging from food to pharmaceuticals. Indeed, one of the most promising areas for CBD is cosmetics.

According to the assertions put forth by Research and Markets analysts: The global CBD skincare market is projected to reach $7.83 billion by 2030, with a compound annual growth rate (CAGR) of 21.4% from 2025 to 2030.

This paper focuses on the controversy over whether CBD can be converted into THC in the stomach. It clarifies that the conversion conclusions from in vitro simulated experiments cannot be equated with the actual in vivo situation, where only trace amounts of conversion occur and no psychoactive effects are produced, and the World Health Organization has also recognized CBD’s high tolerability. The extreme data in some studies is linked to the commercial interests of relevant enterprises; such profit-driven research is likely to interfere with the cognition of the public and regulatory authorities, and vigilance is needed to maintain the healthy development of the industry.

Cannabidiol (CBD), a non-psychoactive compound from hemp and cannabis, has emerged as a trusted natural aid for daily health. It offers versatile benefits—from easing stress and enhancing sleep quality to soothing discomfort and supporting skin health—without inducing a "high." Available in various forms like topicals, edibles, and oils, it seamlessly fits into daily routines for athletes, professionals, and wellness enthusiasts alike. With strong safety profiles and growing scientific backing, CBD remains a popular choice for holistic well-being.

A study by National Cheng Kung University (Taiwan) published in Psychopharmacology shows that cannabidiol (CBD) enhances social learning and memory in male C57BL/6J mice. Administered at 20 mg/kg, CBD strengthens socially transmitted food preference—both short-term and long-term—by boosting acetylcholine signaling in the basal forebrain, dependent on muscarinic acetylcholine receptors. CBD did not affect food intake, locomotion, odor discrimination, or basic social behaviors, and its anxiety-reducing effect did not interfere with memory. Limitations include a single CBD dose and testing only healthy young male mice; future research should explore broader applicability and mechanisms.

Multiple government/federally funded studies show CBD (non-intoxicating cannabidiol) reduces age-related brain inflammation and improves cognition/memory, validated in mice. Cannabis use links to better cognitive performance and lower SCD risk, with no proven significant psychosis risk or brain structure changes—some traditional concerns are overstated, but long-term effects need more research.